Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s management team will participate at the following conferences in September, as detailed below:
Baird Global Healthcare Conference (September 13-14, 2022)
Location: InterContinental New York Barclay, Morgan Suite, Mezzanine Level
Presentation: Tuesday, September 13, 2022, 10:50AM ET (Session IV)
11th Annual SVB Securities Healthcare Summit (September 21-23, 2022)
Location: Rosewood Miramar Beach, Montecito, California
Ladenburg Thalmann Annual Healthcare Conference (September 29, 2022)
Location: Sofitel Hotel, New York, NY, Track 3 – Montmarte
Fireside Chat: Thursday, September 29, 2022, 11:00 AM ET
Links to the presentations will be posted on the Investors section of the Reneo Pharmaceuticals corporate website, under Events and Presentations.
About Reneo Pharmaceuticals
Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, REN001, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation and may increase production of new mitochondria. For additional information, please see reneopharma.com.
Contacts:
Joyce Allaire
Managing Director
LifeSci Advisors, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
Danielle Spangler
Investor Relations
Reneo Pharmaceuticals, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$16.60 |
Daily Volume: | 56,405 |
December 10, 2024 November 05, 2024 November 01, 2024 October 04, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB